Novel and Innovative Drug Delivery Systems to Overcome Chemoresistance in Human Malignancies
- 1st Edition - March 1, 2026
- Editors: Shuvomoy Banerjee, Dhiraj Bhatia, Banerjee
- Language: English
- Paperback ISBN:9 7 8 - 0 - 4 4 3 - 4 5 7 1 7 - 3
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 4 5 7 1 8 - 0
Novel and Innovative Drug Delivery Systems to Overcome Chemoresistance in Human Malignancies addresses the critical challenge of cancer chemoresistance, synthesizing insigh… Read more
Novel and Innovative Drug Delivery Systems to Overcome Chemoresistance in Human Malignancies addresses the critical challenge of cancer chemoresistance, synthesizing insights from cancer biology, molecular biology, biotechnology, and nanotechnology. This book explores the complex mechanisms underlying drug resistance, including alterations in key signaling pathways and the tumor microenvironment's role in cancer cell survival. It highlights advancements in drug delivery technologies, such as nanomedicine and biomimetic strategies, which enhance drug targeting and minimize off-target effects. The integration of techniques like CRISPR-Cas9 and artificial intelligence in developing next-generation therapies is also emphasized. For an academic audience, this book serves as an essential resource to foster interdisciplinary collaboration in cancer research. It equips researchers, clinicians, and industry professionals with the knowledge needed to navigate the evolving landscape of cancer therapeutics, addressing critical challenges in drug delivery and chemoresistance to improve patient outcomes.
- Combines knowledge from cancer biology, molecular biology, biotechnology, and nanotechnology to provide a comprehensive understanding of chemoresistance and innovative drug delivery systems
- Showcases the latest advancements in drug delivery methods, including nanomedicine and biomimetic strategies, emphasizing their potential to enhance therapeutic efficacy and minimize off-target effects
- Presents solutions to overcome cancer chemoresistance, equipping researchers, clinicians, and industry professionals with essential knowledge to navigate the evolving landscape of cancer therapeutics
Researchers and Academics in oncology, cancer biology, molecular biology, and drug development
1. Introduction to Cancer Chemoresistance: Mechanisms and Challenges
2. Impact of Hypoxia, Angiogenesis, and Immune Suppression in Chemoresistance
3. Design and Applications of Nanoparticles, Liposomes, Dendrimers, and Smart Biomaterials-Based Drug Delivery Systems
4. Immunomodulatory Drug Delivery Systems
5. Stimuli-Responsive Drug Delivery Platforms
6. RNA-Based Therapeutics for Overcoming Chemoresistance
7. Drug Repurposing Approaches to Overcome Chemoresistance
8. CRISPR/Cas9 and Gene Editing Approaches as Solutions for Chemoresistance
9. Challenges and Clinical Applications of Novel Drug Delivery Systems
10. Exosome and Extracellular Vesicle-Based Therapeutics
11. Preclinical Models for Evaluating Drug Delivery Systems
12. AI and Machine Learning-Based Drug Design for Overcoming Chemoresistance
2. Impact of Hypoxia, Angiogenesis, and Immune Suppression in Chemoresistance
3. Design and Applications of Nanoparticles, Liposomes, Dendrimers, and Smart Biomaterials-Based Drug Delivery Systems
4. Immunomodulatory Drug Delivery Systems
5. Stimuli-Responsive Drug Delivery Platforms
6. RNA-Based Therapeutics for Overcoming Chemoresistance
7. Drug Repurposing Approaches to Overcome Chemoresistance
8. CRISPR/Cas9 and Gene Editing Approaches as Solutions for Chemoresistance
9. Challenges and Clinical Applications of Novel Drug Delivery Systems
10. Exosome and Extracellular Vesicle-Based Therapeutics
11. Preclinical Models for Evaluating Drug Delivery Systems
12. AI and Machine Learning-Based Drug Design for Overcoming Chemoresistance
- Edition: 1
- Published: March 1, 2026
- Language: English
SB
Shuvomoy Banerjee
Dr. Shuvomoy Banerjee is an accomplished academic and researcher with extensive experience as an editorial board member for several reputable journals, including Reviews in Medical Virology, and as an associate editor for the IAR University Journal. He holds a Ph.D. in cancer biology from Bose Institute, Kolkata, and has post-doctoral research experience at the University of Pennsylvania and Beckman Research Institute. Currently an Assistant Professor at the Institute of Advanced Research, Gandhinagar, Dr. Banerjee specializes in cancer immunology and tumor virology. His prolific contributions include numerous publications in high-impact journals. He has led multiple extramural research projects funded by organizations such as the Science and Engineering Research Board (SERB) and the Gujarat State Biotechnology Mission. His active participation in various scientific organizations underscores his credibility and thought leadership in the field of cancer research.
Regenerate responseAffiliations and expertise
Institute of Advanced Research (IAR), IndiaDB
Dhiraj Bhatia
Dr. Dhiraj Bhatia, an associate professor at IIT-Gandhinagar, specializes in DNA nanotechnology, chemical biology, and drug delivery systems. With a Ph.D. from NCBS-TIFR and postdoctoral work including an HFSP fellowship at Institut Curie, he has pioneered research in structural DNA nanotechnology for biomedical applications. His publications in high-impact journals like ACS Nano, Nature Nanotechnology, and Angewandte Chemie showcase his expertise. His work on programmable DNA nanodevices, hydrogels, and targeted drug delivery addresses critical challenges such as cancer chemoresistance. Recognized with awards like the Merck Young Scientist Award and INYAS-INSA Membership, Dr. Bhatia is also an experienced reviewer and mentor, actively organizing interdisciplinary conferences
Affiliations and expertise
Indian Institute of Technology (IIT), India